Evidence map›Paper›PMID 29216197›Full record

ArticlePloS one2017

Shift toward greater pathologic post-myocardial infarction remodeling with loss of the adaptive hypertrophic signaling of alpha1 adrenergic receptors in mice.

Che-Chung Yeh, Yanying Fan, Yanchun Xu, Yi-Lin Yang, Paul C Simpson, Michael J Mann

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. A (AlphaJACC. Basic to translational science · 2024
    Article
  4. Signaling pathways and targeted therapy for myocardial infarction.Signal transduction and targeted therapy · 2022
    Review
  5. Article
  6. Article
  7. Cardiac α1A-adrenergic receptors: emerging protective roles in cardiovascular diseases.American journal of physiology. Heart and circulatory physiology · 2021
    Review
  8. Current Developments on the Role of αFrontiers in cell and developmental biology · 2021
    Review
  9. Article
  10. ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Che-Chung YehCardiothoracic Translational Research Laboratory, University of California San Francisco, San Francisco, California, United States of America.
Yanying FanCardiothoracic Translational Research Laboratory, University of California San Francisco, San Francisco, California, United States of America.
Yanchun XuCardiothoracic Translational Research Laboratory, University of California San Francisco, San Francisco, California, United States of America.
Yi-Lin YangCardiothoracic Translational Research Laboratory, University of California San Francisco, San Francisco, California, United States of America.
Paul C SimpsonDivision of Cardiology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, United States of America.
Michael J MannCardiothoracic Translational Research Laboratory, University of California San Francisco, San Francisco, California, United States of America.ORCID http://orcid.org/0000-0002-1304-0971
University of California, San Francisco · USSan Francisco VA Medical Center · US

Funding

CATECHOLAMINES AND HYPERTROPHY OF CULTURED HEART CELLSR01HL031113 · NHLBI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI SIMPSON, PAUL C · 1985 to 2021
$5.7M
ERK Signaling and a Hybrid Surgical/Molecular Approach for Chronic Heart FailureR01HL083118 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MANN, MICHAEL J · 2006 to 2016
$4.2M
The role of S1P signaling in surgical cardiac remodelingK08HL079239 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MANN, MICHAEL J · 2006 to 2010
$609k
Novel adrenergic mechanisms in heart failure therapyI01BX004314 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI TEERLINK, JOHN R. · 2019 to 2022
–
NHLBI NIH HHS K08 HL079239NHLBI NIH HHS R01 HL031113NHLBI NIH HHS R01 HL083118
6 · The paper itself

Abstract

rationaleWe have hypothesized that post-infarction cardiac remodeling can be influenced by shifts in the balance between intracellular mediators of "pathologic" and "physiologic" hypertrophy. Although alpha1 adrenergic receptors (alpha1-ARs) mediate pro-adaptive hypertrophy during pressure overload, little is known about their role or downstream mediators after myocardial infarction.

methodsWe performed loss-of-function experiments via coronary ligation in alpha1A-AR knockout (AKO) mice. Post-myocardial infarction (MI) remodeling was evaluated via echocardiography, quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis of cardiac fetal gene expression, histologic analysis of myocyte size, post-MI fibrosis and apoptosis, and Western blot analysis of apoptotic regulators.

resultsAlpha1A-AR knockout paradoxically increased post-MI hypertrophy compared to wild type controls (WT), but also increased ventricular dilatation, fibrosis, apoptosis, and 4-week post-MI mortality (64% in AKO vs. 25% in WT, P = 0.02), suggesting a shift toward greater pathologic hypertrophy in the absence of pro-adaptive alpha1A effects. alpha1A-AR knockout increased phospho-p38 levels in the pre-MI myocardium compared to WT (0.55 ± 0.16 vs. 0.03 ± 0.01, P<0.05) but decreased phospho-ERK1/2 post-MI (0.49 ± 0.35 arbitrary units vs. 1.55 ± 0.43 in WT, P<0.05). Furthermore, expression of pro-apoptotic factor Bax was increased (1.19 ± 0.15 vs. 0.78 ± 0.08, P<0.05) and expression of anti-apoptotic factors Bcl2 was decreased (0.26 ± 0.01 vs. 0.55 ± 0.06, P<0.01) compared to WT.

conclusionsAlpha1A-AR provides an important counterbalance to pathologic pathways during post-MI remodeling that may be mediated through ERK1/2 signaling; these observations provide support for further development of an alpha1A-AR/ERK-based molecular intervention for this chronic, often fatal disease.

Indexed as

MAP Kinase Signaling SystemVentricular RemodelingAngiotensin-Converting Enzyme InhibitorsAnimalsCaptoprilMaleMiceMice, KnockoutMyocardial InfarctionReceptors, Adrenergic, alpha-1Angiotensin-Converting Enzyme InhibitorsCaptoprilReceptors, Adrenergic, alpha-1

Identifiers

PMID29216197
PMCPMC5720786
OpenAlexW2772221195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.